New scan could replace risky vein test for curable high blood pressure

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Getting the written informed consent; * PA conccurent with autonomous cortisol secretion; * Patients with hypertension aged 18-70 years; * CT or MRI scan of the adrenal glands with adenoma. Exclusion criteria Exclusion Criteria: * Unable to complete 68Ga-Pentixafor PET/CT or AVS; * Refusal of surgery or contraindications for surgery; * PA patients who meet the by-passing AVS criteria \[i.e., younger than 35 years old, spontaneous hypokalemia, adrenal CT indicated unilateral low-density adenoma (≥1cm), plasma aldosterone \>300pg/ml\] * Suspicion of familial hyperaldosteronism or Liddle syndrome. \[i.e., age \<20 years, hypertension and hypokalemia, or with family history\]; * Suspicion of pheochromocytoma or adrenal carcinoma; * Patients with actively malignant tumor; * Patients who have adrenalectomy history; * Long-term use of glucocorticoids; * Pregnant or lactating women; with alcohol or drug abuse and mental disorders; * Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV; History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 3 months; Severe anemia (Hb\<60g/L); Serious liver dysfunction or chronic kidney disease aspartate aminotransferase (AST) or alanine transaminase (ALT) \>3 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73 m2); Systemic Inflammatory Response Syndrome (SIRS); Uncontrolled diabetes (FBG≥13.3 mmol/L); Obesity (BMI≥35 kg/m²) or Underweight (BMI≤18 kg/m²); Untreated aneurysm; Other comorbidity potentially interfering with treatment; * Suspected PBMAH or PPNAD; * Poor compliance or any other reason deemed unsuitable for inclusion by the investigators; * Patients with adrenal insufficiency requiring hormone replacement therapy.